Xintela AB

XINT · Nasdaq Stockholm · Healthcare

0.17SEK −2.8%last day

Price as of 2 October 2026

The price over the past year, with dividends: −57.4%

Performance

1 month

+9.1%

1 year

−57.4%

3 years, per year

−12.4%

5 years, per year

−32.8%

Largest fall, 3 years

−90.2%

Below the peak now

−96.3%

Volatility, 1 year

73.8%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

−6.4

Dividend yield

0.0%

Return on equity

−175.3%

Net margin

–

Market value

15 m USD

Quality, value and trend

Where Xintela stands against every Nordic stock today. 100 is best.

Quality46

Profitability and a sound balance sheet over time. Better than 46% of Nordic stocks.

Value1

The price measured against earnings, assets and cash flow. Better than 1% of Nordic stocks.

Trend8

The price development over the past year. Better than 8% of Nordic stocks.

Combined4

Quality, value and trend together. Better than 4% of Nordic stocks.

About Xintela

Xintela AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 11 employees.

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis